Protein Therapeutics Market Size was valued at USD 182.1 billion in 2022. The Protein Therapeutics market industry is projected to grow from USD 194.59 Billion in 2023 to USD 330.86 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.9% during the forecast period (2024 - 2032). Increasing prevalence of chronic diseases, rising demand for personalized medicine, advances in biotechnology and genetic engineering, increasing investment in research and development, and growing demand for biosimilars are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Chronic diseases such as cancer, diabetes, and autoimmune disorders are becoming increasingly prevalent worldwide. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths ly. Protein therapeutics are often used to treat these conditions, driving growth in the market.
Advances in biotechnology have made it possible to produce complex proteins on a large scale. This has led to the development of new and improved protein therapeutics, including monoclonal antibodies, fusion proteins, and recombinant proteins. These new therapies are driving growth in the market. Furthermore, Pharmaceutical companies are investing heavily in research and development to develop new protein therapeutics.
Moreover, there is a growing focus on personalized medicine, which involves tailoring treatment to an individual's unique genetic makeup. Protein therapeutics offer several advantages over traditional small molecule drugs, including better specificity and reduced toxicity.
The Protein Therapeutics market segmentation, based on type, includes monoclonal antibodies, insulin, fusion protein, erythropoietin, and interferon. The monoclonal antibodies segment held the majority share in 2022 contribution to the Protein Therapeutics market revenue. This is because they are used to treat cancer, autoimmune diseases, and infectious diseases.
The protein therapeutics market segmentation, based on application, includes cancer, metabolic disorders, immunologic disorders, and hematological disorders. The cancer segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2030. Monoclonal antibodies are used to target specific cancer cells and prevent their growth. Protein therapeutics are also used to treat autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis.
February 2021 Sanofi announced that it had completed the acquisition of Kymab, a UK-based biotech company focused on developing antibody therapeutics. The acquisition gives Sanofi access to Kymab's proprietary antibody technology platform, which can be used to develop next-generation immunotherapies for cancer and other diseases.
The Protein Therapeutics market data has been bifurcated by end user into hospitals & clinics, and specialty centers. The hospitals & clinics end user segment dominated the market in 2022. This is due to these drugs provided by hospitals & clinics are primarily used for patient treatment. Research institutions use protein therapeutics for preclinical and clinical studies to evaluate their safety and efficacy. Pharmaceutical and biotechnology companies are also significant end-users of protein therapeutics, as they develop and market these drugs to treat various diseases and disorders. Overall, the demand for protein therapeutics continues to grow, driven by the increasing prevalence of chronic and rare diseases and the need for safe and effective treatments.
Figure 1 Protein Therapeutics Market, by End User, 2023 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Protein Therapeutics Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America protein therapeutics market accounted for USD 83.40 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The region is driven by the high prevalence of chronic diseases, well-established healthcare infrastructure, and favorable reimbursement policies are key factors driving the growth of the protein therapeutics market in North America. Additionally, the presence of major pharmaceutical and biotechnology companies in the region has led to increased investments in research and development, leading to the development of new and innovative protein therapeutics.
Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 PROTEIN THERAPEUTICS MARKET SHARE BY REGION 2023 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Protein Therapeutics market accounts for the second-largest market share. The market is driven by the increasing prevalence of chronic diseases, rising demand for biologics, and favorable government policies supporting the development and commercialization of protein therapeutics. Additionally, the increasing number of clinical trials in the region is expected to contribute to the growth of the protein therapeutics market. Further, the Germany Protein Therapeutics market held the largest market share, and the UK Protein Therapeutics market was the fastest growing market in the European region due to the high demand for Protein Therapeutics and the presence of several major manufacturers in the country.
The Asia-Pacific Protein Therapeutics market is expected to grow at the fastest CAGR from 2024 to 2030. The market is driven by the increasing healthcare expenditure, rising prevalence of chronic diseases, and the increasing adoption of biologics. Japan, China, and India are the major contributors to the protein therapeutics market in the Asia-Pacific region. Moreover, China Protein Therapeutics market held the largest market share, and the India Protein Therapeutics market was the fastest growing market in the Asia-Pacific region. In China, the increasing focus on healthcare reforms and the availability of low-cost manufacturing capabilities are driving the growth of the protein therapeutics market. In India, the increasing investment in healthcare infrastructure and favorable government policies supporting the development of biologics are expected to contribute to the growth of the protein therapeutics market.
Protein Therapeutics Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Protein Therapeutics market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Protein Therapeutics industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Protein Therapeutics industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Protein Therapeutics industry has provided innovative products with some of the most significant benefits. The Protein Therapeutics market major player such as Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co. Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc (US), Sanofi (France) and others are working to expand the market demand by investing in research and development activities.
Sanofi is a biopharmaceutical company headquartered in Paris, France. It focused on developing innovative therapies in the areas of immunology, oncology, rare diseases, and vaccines. Sanofi has a diverse portfolio of products and a strong presence in emerging markets. In recent years, Sanofi has been expanding its capabilities in biologics and specialty care through strategic partnerships and acquisitions. The company's pipeline includes several promising therapies in oncology and rare diseases, as well as vaccines for COVID-19 and other infectious diseases. In May 2019, Sanofi announced a partnership with Denali Therapeutics to develop a portfolio of molecules for the treatment of neurological and systemic inflammatory diseases.
Merck & Co., Inc., also known as MSD outside of the United States and Canada, is a biopharmaceutical company headquartered in Kenilworth, New Jersey, USA. The company is focused on developing innovative therapies in the areas of oncology, vaccines, infectious diseases, and animal health. Merck has a strong pipeline of drugs and vaccines, with several promising candidates in late-stage clinical trials. In January 2021, Merck announced a partnership with Debiopharm to develop and commercialize Xevinapant, a protein that inhibits apoptosis, for the treatment of various cancers.
Key Companies in the Protein Therapeutics market includes
Protein Therapeutics Industry Developments
March 2020 Biogen completed the acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
March 2020 AstraZeneca announced a partnership with Daiichi Sankyo to develop and commercialize trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate, for the treatment of breast and gastric cancers.
April 2020 Amgen announced the launch of its biosimilar version of Avastin (bevacizumab), which is used to treat certain types of cancer.
July 2020 Roche announced the launch of its hemophilia A treatment Hemlibra (emicizumab) in India.
November 2020 Pfizer announced the acquisition of Amplyx Pharmaceuticals, a clinical-stage biotech company focused on developing small molecule therapeutics for the treatment of infectious diseases.
December 2020 Eli Lilly and Company announced a partnership with Precision BioSciences to develop gene-edited cell therapies for the treatment of genetic disorders.
January 2021 Merck announced a partnership with Debiopharm to develop and commercialize Xevinapant, a protein that inhibits apoptosis, for the treatment of various cancers.
May 2021 Novartis announced the launch of its gene therapy Zolgensma (onasemnogene abeparvovec) in Japan for the treatment of spinal muscular atrophy.
Protein Therapeutics Regional Outlook
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 182.1 billion |
| Market Size 2023 | USD 194.59 billion |
| Market Size 2032 | USD 330.86 billion |
| Compound Annual Growth Rate (CAGR) | 6.9% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co. Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc (US), and Sanofi (France) |
| Key Market Opportunities | Advances in biotechnology and Increasing investment in research and development |
| Key Market Dynamics | Increasing prevalence of chronic diseases |
Protein Therapeutics Market Highlights:
Frequently Asked Questions (FAQ) :
The Protein Therapeutics market size was valued at USD 182.1 Billion in 2022.
The market is projected to grow at a CAGR of 6.9% during the forecast period, 2024 -2032.
North America had the largest share in the market
The key players in the market are Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co. Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc (US), and Sanofi (France).
The cancer protein therapeutics application dominated the market in 2022.
The hospitals and clinics had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
